Abstract
Objective
Liraglutide is a commonly used hypoglycemic agent in clinical practice, and has been demonstrated to have protective effects against the development of cardiovascular disease. However, its potential role in myocardial fibrosis remains unexplored. The present study aims to assess the impact of liraglutide on the activation of cardiac fibroblasts.
Methods
Primary rat adult fibroblasts were isolated, cultured, and randomly allocated into 4 groups: control group, transforming growth factor beta1 (TGFβ1) stimulation group, liraglutide group, and TGFβ1+liraglutide group. Fibroblast activation was induced by TGFβ1. Cell proliferation activity was assessed using the CKK-8 kit, and cellular activity was determined using the MTT kit. Reverse transcrition-quantitative polymerase chain reaction (RT-qPCR) was utilized to quantify the level of collagen transcription, immunofluorescence staining was performed to detect the expression level of type III collagen and α-smooth muscle protein (α-SMA), and immunoblotting was conducted to monitor alterations in signal pathways.
Results
The addition of 10, 25, 50 and 100 nmol/L of liraglutide did not induce any significant impact on the viability of fibroblasts (P>0.05). The rate of cellular proliferation was significantly higher in the TGFβl stimulation group than in the control group. However, the treatment with 50 and 100 nmol/L of liraglutide resulted in the reduction of TGFβl-induced cell proliferation (P<0.05). The RT-qPCR results revealed that the transcription levels of type I collagen, type III collagen, and α-SMA were significantly upregulated in the TGFβl stimulation group, when compared to the control group (P<0.05). However, the expression levels of these aforementioned factors significantly decreased in the TGFβl+liraglutide group (P<0.05). The immunofluorescence staining results revealed a significant increase in the expression levels of type III collagen and α-SMA in the TGFβl stimulation group, when compared to the control group (P<0.05). However, these expression levels significantly decreased in the TGFβl+liraglutide group, when compared to the TGFβl stimulation group (P<0.05). The Western blotting results revealed that the expression levels of phosphorylated smad2 and smad3 significantly increased in the TGFβl stimulation group, when compared to the control group (P<0.05), while these decreased in the TGFβl+liraglutide group (P<0.05).
Conclusion
Liraglutide inhibits myocardial fibrosis development by suppressing the smad signaling pathway, reducing the activation and secretion of cardiac fibroblasts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides, 2019,111:26–32
Andrikou E, Tsioufis C, Andrikou I, et al. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol, 2019,60(6):347–351
Le Y, Wei R, Yang K, et al. Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways. Peptides, 2020,124:170212
Li J, Oltjon A, Zhuo M, et al. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. Clin J Am Soc Nephrol, 2020,15(11):1678–1688
Noyan-Ashraf MH, Momen MA, Kiwon B, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 2009,58(4):975–983
Li R, Shan Y, Gao L, et al. The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling. Front Pharmacol, 2019,10:537
Plikus MV, Wang X, Sinha S, et al. Fibroblasts: Origins, definitions, and functions in health and disease. Cell,2021,184(15):3852–3872
Kurose H. Cardiac Fibrosis and Fibroblasts. Cells, 2021,10(7):1716
Park S, Nguyen NB, Pezhouman A, et al. Cardiac fibrosis: potential therapeutic targets. Transl Res, 2019,209:121–137
Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci, 2018,14(12):1645–1657
Wu QQ, Xiao Y, Yuan Y, et al. Mechanisms contributing to cardiac remodelling. Clin Sci (Lond), 2017,131(18):2319–2345
Liu M, Feng J, Du Q, et al. Paeoniflorin Attenuates Myocardial Fibrosis in Isoprenaline-induced Chronic Heart Failure Rats via Inhibiting P38 MAPK Pathway. Curr Med Sci, 2020,40(2):307–312
Kyselovic J, Leddy JJ. Cardiac Fibrosis: The Beneficial Effects of Exercise in Cardiac Fibrosis. Adv Exp Med Biol, 2017,999: 257–268
Yue Y, Meng K, Pu Y, et al. Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract, 2017,133:124–130
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The authors declare that they have no conflicts of interest.
Additional information
This project was supported by grants from the Natural Science Foundation of Hubei Province (No. 2022CFB671), Health Research Project of Hubei Province (No. WJ2023F020) and Hubei Province Key Laboratory Open Project (No. 2021KFY023).
Rights and permissions
About this article
Cite this article
Sun, W., Mi, H., He, Dy. et al. Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway. CURR MED SCI 43, 955–960 (2023). https://doi.org/10.1007/s11596-023-2776-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-023-2776-8